Premium
A molecular monopoly? HPV testing, the Pap smear and the molecularisation of cervical cancer screening in the USA
Author(s) -
Hogarth Stuart,
Hopkins Michael M.,
Rodriguez Victor
Publication year - 2012
Publication title -
sociology of health and illness
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.146
H-Index - 97
eISSN - 1467-9566
pISSN - 0141-9889
DOI - 10.1111/j.1467-9566.2011.01411.x
Subject(s) - context (archaeology) , cervical cancer , monopoly , business , mainstream , statutory law , marketing , political science , medicine , cancer , economics , law , history , archaeology , market economy
DNA‐based molecular testing for human papillomavirus has emerged as a novel approach to cervical cancer screening in the context of well‐entrenched existing technology, the Pap smear. This article seeks to elucidate the process of molecularisation in the context of screening programmes. We illustrate how, although Pap has long been problematised and could be seen as a competing technological option, the existing networks and regime for Pap were important in supporting the entrenchment process for the artefacts, techniques and new diagnostics industry entrant, Digene, associated with the new test. The article provides insights into how the molecularisation of screening unfolds in a mainstream market. We reveal an incremental and accretive, rather than revolutionary, process led by new commercial interests in an era when diagnostic innovation is increasingly privatised. We show Digene’s reliance on patents, an international scientific network and their position as an obligatory point of passage in the clinical research field with regard to the new technology’s role, as well as on controversial new marketing practices. The article is based on a mixed method approach, drawing on a wide range of contemporary sources (including patents, statutory filings by companies, scientific literature and news sources) as well as interviews.